Neumora Therapeutics falls after US FDA puts schizophrenia drug study on hold

Neumora Therapeutics

15/04/2024 12:13

** Shares of drug developer Neumora Therapeutics  NMRA.O 
fall 22.5% to $10.51 premarket 
    ** Co says the U.S. Food and Drug Administration (FDA) has
placed a clinical hold on the early-stage study of its
schizophrenia drug candidate
    ** Schizophrenia is a serious mental illness which involves
a disconnection from reality, including hallucinations and
delusions
    ** The FDA's clinical hold follows recently available
pre-clinical data showing convulsions in rabbits    
    ** Says co has paused the study in which 30 participants
were dosed with no evidence of convulsions observed 
    ** Says NMRA is working with FDA to evaluate the potential
to resolve the clinical hold  
    ** The company that is backed by Amgen  AMGN.O  and Japan's
SoftBank  9434.T  debuted on the Nasdaq in September
    ** Up to last close, stock down 20.5% YTD  

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))